April 2007
If you take Zelnorm to treat irritable bowel syndrome (IBS) or constipation, you may be at serious risk of heart attack or stroke. Following several clinical trials, the Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals discontinue selling the gastrointestinal (GI) drug, Zelnorm.
Zelnorm is used to treat chronic constipation in men and women under 65, as well as irritable bowl system in women. But clinical trials have proven that the risks outweigh the benefits for most patients.
Studies conducted through the manufacturer showed that angina, heart attack, and stroke were potential risks. Patients currently taking Zelnorm should consult their healthcare professionals to determine alternative treatments.